471820 — Cellromax Science Co Balance Sheet
0.000.00%
- KR₩58bn
- KR₩37bn
- KR₩22bn
- 75
- 58
- 24
- 54
Annual balance sheet for Cellromax Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Equivalents | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 5,148 | 7,044 | 11,800 | 22,732 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 1,675 | 621 | 602 | 641 |
Total Inventory | ||||
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 12,348 | 13,244 | 17,120 | 30,878 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 5,395 | 5,180 | 5,533 | 3,661 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Other Long Term Assets | ||||
Total Assets | 23,994 | 28,530 | 32,827 | 49,100 |
Accounts Payable | ||||
Payable / Accrued | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 2,796 | 2,610 | 2,353 | 3,154 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Funded Status | ||||
Total Liabilities | 2,976 | 2,765 | 2,713 | 4,579 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Other Equity | ||||
Total Equity | 21,018 | 25,765 | 30,115 | 44,522 |
Total Liabilities & Shareholders' Equity | 23,994 | 28,530 | 32,827 | 49,100 |
Total Common Shares Outstanding |